In a collaboration between researchers in Norway (Oslo University Hospital/University of Oslo and Nextera AS), USA (John Hopkins University) and Australia (Monash University), Nextera’s unique NextCore-Ab technology was employed to generate and characterize extremely sensitive TCR-Like antibodies towards gluten T cell epitopes. Their utility expand insight into celiac disease pathogenesis and opens the door for targeted therapeutic intervention
Nextera’s unique pVII phage display technology expands insights into the biology of human FSAP haemostasis
In ChemBioChem we describe the employment of Nextera’s pVII peptide phage display technology in the fine-mapping of FSAP enzyme substrate specificity, which shows surprising new results.
A better understanding of immunological principles is at the core of Nextera’s efforts to contribute to robust drug development in complex diseases.